Hypercholesterolemia – Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040
- Published Date : November 11, 2025
- Updated On : June 15, 2026
- Pages : 52
Hypercholesterolemia Global Epidemiology Insights and Disease Burden
Thelansis’s “Hypercholesterolemia Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Hypercholesterolemia Overview
Hypercholesterolemia is characterized by elevated low-density lipoprotein cholesterol (LDL-C), serving as the primary causal driver of atherosclerotic cardiovascular disease (ASCVD). While largely polygenic, severe monogenic forms like familial hypercholesterolemia (FH)—driven by LDLR, APOB, or PCSK9 mutations—confer an exponentially higher risk of premature myocardial infarction. The condition remains predominantly asymptomatic until a cardiovascular event occurs, though severe FH may manifest with tendinous xanthomas or corneal arcus. Diagnosis relies on lipid panels, with an LDL-C >190 mg/dL strongly indicating phenotypic FH and prompting cascade genetic screening. The therapeutic mandate is aggressive LDL-C reduction. First-line management universally anchors on high-intensity statins and ezetimibe. For statin-intolerant, refractory, or FH patients, the landscape has been completely transformed by targeted agents: PCSK9 monoclonal antibodies (evolocumab, alirocumab) and the twice-yearly siRNA inclisiran provide profound LDL-C clearance. Oral bempedoic acid offers a critical non-statin adjunct. Crucially, for the extreme homozygous FH phenotype, ANGPTL3 inhibitors like evinacumab now bypass the defective LDL receptor pathway entirely, delivering life-altering LDL-C reductions in historically untreatable patients.
Market Definition:
- North America (United States, Canada)
- Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
- Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
- Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt, Nigeria, South Africa, Morocco)
- South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)
Deliverables format and updates*:
- Access to an interactive epidemiology platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional findings
- Country-specific findings
- Others*: regular updates, customizations, epidemiologist support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
Key business questions answered:
- 20-year historical and forecast data (2020–2040)
- Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage by year and geography
- Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g., staging/classification/severity)
Insights driven by robust research and estimates:
- Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR datasets
- Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)
Hypercholesterolemia Global Epidemiology Insights and Disease Burden
Thelansis’s “Hypercholesterolemia Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Hypercholesterolemia Overview
Hypercholesterolemia is characterized by elevated low-density lipoprotein cholesterol (LDL-C), serving as the primary causal driver of atherosclerotic cardiovascular disease (ASCVD). While largely polygenic, severe monogenic forms like familial hypercholesterolemia (FH)—driven by LDLR, APOB, or PCSK9 mutations—confer an exponentially higher risk of premature myocardial infarction. The condition remains predominantly asymptomatic until a cardiovascular event occurs, though severe FH may manifest with tendinous xanthomas or corneal arcus. Diagnosis relies on lipid panels, with an LDL-C >190 mg/dL strongly indicating phenotypic FH and prompting cascade genetic screening. The therapeutic mandate is aggressive LDL-C reduction. First-line management universally anchors on high-intensity statins and ezetimibe. For statin-intolerant, refractory, or FH patients, the landscape has been completely transformed by targeted agents: PCSK9 monoclonal antibodies (evolocumab, alirocumab) and the twice-yearly siRNA inclisiran provide profound LDL-C clearance. Oral bempedoic acid offers a critical non-statin adjunct. Crucially, for the extreme homozygous FH phenotype, ANGPTL3 inhibitors like evinacumab now bypass the defective LDL receptor pathway entirely, delivering life-altering LDL-C reductions in historically untreatable patients.
Market Definition:
- North America (United States, Canada)
- Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
- Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
- Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt, Nigeria, South Africa, Morocco)
- South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)
Deliverables format and updates*:
- Access to an interactive epidemiology platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional findings
- Country-specific findings
- Others*: regular updates, customizations, epidemiologist support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
Key business questions answered:
- 20-year historical and forecast data (2020–2040)
- Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage by year and geography
- Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g., staging/classification/severity)
Insights driven by robust research and estimates:
- Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR datasets
- Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)